NLEP for Prof exam with visualizelearning
Asking for Preferences
What is the subject/topic for the NLEP (Note/Lesson/Exam Prep)? Β· Which Professional exam are you preparing for?
Asking for Preferences
What specific topic or disease would you like the NLEP notes with visual learning for? (e.g., Tuberculosis, Heart failure, Renal physiology, Antihypertensives...)
It looks like you'd like to type in a specific topic. Could you please tell me:
- What topic/disease would you like the NLEP for? (e.g., "Typhoid fever", "Glomerulonephritis", "Beta blockers", etc.)
- Which professional exam are you preparing for? (e.g., USMLE Step 1, MBBS Final Prof, FMGE, etc.)
Once I know the topic and exam, I'll build you a structured NLEP (Note - Learning points - Exam Pearls) with visual aids, mnemonics, and high-yield exam content.
National leprosy eradication programme
Reading File
NLEP (National Leprosy Eradication Programme) is a high-yield topic for Community Medicine / PSM professional exams. Searching the textbook library now.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
National Leprosy Eradication Programme NLEP India 2024 key features MDT
Now let me read the Park's textbook sections on NLEP in detail.
Reading File
Reading File
Reading File
Reading File
Reading File
National leprosy eradication programme for mbbs 3rd part 1
Reading File
Finding Sources
Searching the Web
NLEP National Leprosy Eradication Programme India MDT regimen 2025 MBBS PSM exam
Reading File
Reading Web Page
https://dghs.mohfw.gov.in/nlep.php
Reading File
Reading File
Reading File
I now have comprehensive data. Let me generate the visual diagram and compile the full NLEP notes.
Loading Image
Generating Image
A clean, colorful medical study diagram titled "NLEP - National Leprosy Eradication Programme" for MBBS students. Shows a flowchart/mind map with: (1) Historical timeline: NLCP 1955 β NLEP 1983 β MDT nationwide β Elimination 2005 β Triple drug 2025; (2) MDT regimen box comparing old PB (2 drugs: Rifampicin + Dapsone, 6 months) vs MB (3 drugs: Rifampicin + Dapsone + Clofazimine, 12 months) and NEW 2025 protocol (both PB and MB get 3-drug regimen); (3) 5 Programme Components listed as colored boxes; (4) Key indicators: PR less than 1/10,000 = elimination; (5) ASHA incentives. Bright educational style with color-coded sections, arrows, and mnemonics.
π NLEP - National Leprosy Eradication Programme
MBBS 3rd Year, Part 1 | Community Medicine / PSM
π§ VISUAL OVERVIEW DIAGRAM
π SECTION 1 - HISTORICAL TIMELINE (High-Yield for MCQ!)
NLCP launched (1955) β MDT recommended by WHO (1981)
β Renamed NLEP (1983) β World Bank support (1993)
β Integrated into GHS (2002β03) β National Elimination achieved (Dec 2005)
β NIKUSTH software launched (2016) β Sparsh Campaign (2017)
β PEP (single-dose Rifampicin) introduced (2017) β ABSULS launched (July 2019)
β Triple drug for PB cases (April 1, 2025)
Mnemonic - "NLEP Milestones": NCP starts '55, renamed '83, Elimination 2005, PEP 2017
π SECTION 2 - DEFINITION OF ELIMINATION vs ERADICATION
| Term | Definition |
|---|---|
| Elimination | Prevalence Rate (PR) < 1 per 10,000 population |
| Eradication | Zero transmission worldwide |
| India's status | National elimination achieved December 2005 |
| Current PR (2024-25) | 0.57 per 10,000 population |
β οΈ Exam Trap: India has achieved elimination, NOT eradication!
π SECTION 3 - PROGRAMME COMPONENTS (5 + 1 New)
βββββββββββββββββββββββββββββββββββββββββββββββββββββββ
β NLEP PROGRAMME COMPONENTS β
β β
β 1. Case Detection & Management (MDT) β
β 2. Disability Prevention & Medical Rehab (DPMR) β
β 3. IEC + Behaviour Change Communication (BCC) β
β 4. Human Resources & Capacity Building β
β 5. Programme Management & Monitoring β
βββββββββββββββββββββββββββββββββββββββββββββββββββββββ
Mnemonic - "CDIPH": Case detection, DPMR, IEC/BCC, Programme management, Human resources
π SECTION 4 - MDT REGIMEN (π₯ MOST HIGH-YIELD TOPIC)
OLD Regimen (Pre-April 2025) - Still asked in exams!
| PB Leprosy | MB Leprosy | |
|---|---|---|
| Classification | β€5 skin lesions, β€1 nerve | >5 skin lesions, >1 nerve |
| Drugs | 2 drugs | 3 drugs |
| Rifampicin | 600 mg monthly (supervised) | 600 mg monthly (supervised) |
| Dapsone | 100 mg daily (self-administered) | 100 mg daily (self-administered) |
| Clofazimine | β NOT given | 300 mg monthly + 50 mg daily |
| Duration | 6 months | 12 months |
π NEW Regimen (From April 1, 2025) - EXAM UPDATE!
Both PB and MB now receive the SAME 3-drug MDT regimen (Uniform MDT)
- Rifampicin + Dapsone + Clofazimine for ALL patients
- Aligns with WHO recommendation
- Goal: Eliminate leprosy transmission by 2027
- Patients already on old regimen before March 31, 2025 continue old regimen until completion
Mnemonic for MDT drugs - "RDC" = Rifampicin, Dapsone, Clofazimine
π SECTION 5 - PROGRAMME MANAGEMENT (Administration)
| Feature | Detail |
|---|---|
| Type | Centrally Sponsored Scheme |
| Ministry | Ministry of Health & Family Welfare, GOI |
| Implementation | States/UTs under NRHM/NHM |
| MDT supply | Free of cost via WHO |
| Technical support | WHO + ILEP (International Federation of Anti-Leprosy Associations) |
| Software | NIKUSTH (real-time reporting, 2016) |
π SECTION 6 - KEY INDICATORS (Monitoring)
| Indicator | Formula / Definition |
|---|---|
| Prevalence Rate (PR) | Active cases per 10,000 population |
| ANCDR | Annual New Case Detection Rate per 1,00,000 population |
| Child case % | % of children (<15 yrs) among new cases (indicates active transmission) |
| Grade 2 Disability (G2D) | % with visible deformity among new cases (indicates late detection) |
| Treatment Completion Rate | % completing full MDT course |
Current National Indicators (2024-25):
- PR = 0.57/10,000 (elimination threshold = <1/10,000) β
- ANCDR = 7.00/1,00,000
- Child cases = 4.68% (down from 9.04% in 2014-15)
- G2D = 1.31 per million (down from 4.48 in 2014-15)
- Districts achieving elimination = 638/638 (100%)
π SECTION 7 - ASHA INCENTIVES (Frequently Asked!)
| ASHA Activity | Incentive |
|---|---|
| Confirmed diagnosis of case brought by ASHA | βΉ 250 |
| PB leprosy case - treatment completion | βΉ 400 |
| MB leprosy case - treatment completion | βΉ 600 |
| Early case before any visible deformity | βΉ 250 (additional) |
| New case with visible deformity | βΉ 200 |
ABSULS (ASHA Based Surveillance for Leprosy Suspects) - launched 1st July 2019
π SECTION 8 - DPMR (Disability Prevention & Medical Rehabilitation)
Three-tier referral system:
| Level | Institutions | Activities |
|---|---|---|
| Primary (1st level) | PHC, CHC, Sub-divisional Hospital, Urban Leprosy Centres | Self-care, MCR footwear, ulcer dressing, counselling |
| Secondary (2nd level) | District Hospital, District Nucleus | Leprosy reactions, complicated ulcers, RCS screening |
| Tertiary (3rd level) | CLTRI (Chingalpet), RLTRI (Aska/Gauripur/Raipur), JALMA-ICMR (Agra), ILEP hospitals | RCS training, difficult cases |
Referral System in NLEP (from Park's textbook, p. 479):
DPMR aids provided:
- Dressing materials + ulcer kits
- MCR (Micro-Cellular Rubber) footwear for insensitive feet
- Reconstructive surgery (RCS) at 83 centres (41 NGO + 42 Govt Medical Colleges)
- βΉ5,000 incentive for BPL patients undergoing RCS
π SECTION 9 - SPECIAL CAMPAIGNS & STRATEGIES
| Campaign/Strategy | Details |
|---|---|
| LCDC | Leprosy Case Detection Campaign - door-to-door surveys |
| Sparsh Leprosy Awareness Campaign | Launched 2017 - reduce stigma |
| PEP | Post-Exposure Prophylaxis with single-dose Rifampicin for contacts (2017) |
| ABSULS | ASHA-based surveillance, 2019 |
| Ayushman Bharat convergence | 2019 |
| RKSK convergence | Rashtriya Kishore Swasthya Karyakaram, 2020 |
| IEC theme | "Towards Leprosy Free India" |
π SECTION 10 - ANTI-LEPROSY ORGANIZATIONS IN INDIA
| Organization | Detail |
|---|---|
| Leprosy Mission | Founded 1874 by Bailey at Chamba, HP |
| Hind Kusht Nivaran Sangh | Formerly British Empire Leprosy Relief Association |
| Gandhi Memorial Leprosy Foundation | Sevagram, Wardha |
| JALMA | Taken over by ICMR in 1975 (Agra) - key research centre |
| National Leprosy Organization | 1965 - umbrella body for all NGOs |
π― EXAM PEARLS (Must Know for Prof Exam!)
- NLCP β NLEP: 1955 β 1983
- Elimination criteria: PR < 1 per 10,000 population
- India achieved elimination: December 2005
- MDT supplied: Free of cost via WHO
- New 2025 update: Both PB and MB get 3-drug MDT (Uniform MDT from April 1, 2025)
- Main monitoring indicator: New Case Detection Rate (NOT prevalence)
- JALMA, Agra = ICMR institute for leprosy research
- CLTRI Chingalpet = Central Leprosy Training & Research Institute
- MCR footwear = Micro-cellular rubber - for insensitive feet
- ASHA for PB completion: βΉ400; MB completion: βΉ600
β‘ QUICK MNEMONICS SUMMARY
| Mnemonic | Meaning |
|---|---|
| RDC | MDT drugs: Rifampicin, Dapsone, Clofazimine |
| CDIPH | NLEP Components |
| "55-83-2005" | NLCP start - NLEP rename - National elimination |
| "1/10,000" | Elimination threshold |
| PEP = 2017 | Single-dose Rifampicin for contacts |
Source: Park's Textbook of Preventive & Social Medicine, pp. 477-480 | DGHS-MoHFW NLEP official data 2024-25
This is a shared conversation. Sign in to Orris to start your own chat.